Carbonic Anhydrase Inhibition as a Target for Antibiotic Synergy in Enterococci

• Published in: Microbiology spectrum 2023-08, Vol.11 (4), p.e0396322-e0396322
• Main Authors: Chilambi, Gayatri Shankar, Wang, Yu-Hao, Wallace, Nathan R, Obiwuma, Chetachukwu, Evans, Kirsten M, Li, Yanhong, Shalaby, Menna-Allah W, Flaherty, Daniel P, Shields, Ryan K, Doi, Yohei, Van Tyne, Daria
• Format: Article
• Language: English
• Subjects: Animals; Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; antibiotic synergy; Antimicrobial Chemotherapy; carbonic anhydrase; Carbonic Anhydrases - genetics; Endocarditis, Bacterial - drug therapy; Endocarditis, Bacterial - microbiology; Enterococcus; Enterococcus faecalis; Gentamicins - pharmacology; Gentamicins - therapeutic use; Gram-Positive Bacterial Infections - microbiology; Humans; Mammals; Microbial Sensitivity Tests; Research Article
• ISSN: 2165-0497; 2165-0497
• DOI: 10.1128/spectrum.03963-22

Enterococcus faecalis is a hospital-associated opportunistic pathogen that can cause infections with high mortality, such as infective endocarditis. With an increasing occurrence of multidrug-resistant enterococci, there is a need for alternative strategies to treat enterococcal infections. We isolated a gentamicin-hypersusceptible E. faecalis strain from a patient with infective endocarditis that carried a mutation in the alpha-carbonic anhydrase (α-CA) and investigated how disruption of α-CA sensitized E. faecalis to killing with gentamicin. The gentamicin-hypersusceptible α-CA mutant strain showed increased intracellular gentamicin uptake in comparison to an isogenic strain encoding full-length, wild-type α-CA. We hypothesized that increased gentamicin uptake could be due to increased proton motive force (PMF), increased membrane permeability, or both. We observed increased intracellular ATP production in the α-CA mutant strain, suggesting increased PMF-driven gentamicin uptake contributed to the strain's gentamicin susceptibility. We also analyzed the membrane permeability and fatty acid composition of isogenic wild-type and α-CA mutant strains and found that the mutant displayed a membrane composition that was consistent with increased membrane permeability. Finally, we observed that exposure to the FDA-approved α-CA inhibitor acetazolamide lowered the gentamicin MIC of eight genetically diverse E. faecalis strains with intact α-CA but did not change the MIC of the α-CA mutant strain. These results suggest that α-CA mutation or inhibition increases PMF and alters membrane permeability, leading to increased uptake of gentamicin into E. faecalis. This connection could be exploited clinically to provide new combination therapies for patients with enterococcal infections. Enterococcal infections can be difficult to treat, and new therapeutic approaches are needed. In studying an E. faecalis clinical strain from an infected patient, we found that the bacteria were rendered hypersusceptible to aminoglycoside antibiotics through a mutation that disrupted the α-CA. Our follow-on work suggested two different ways that α-CA disruption causes increased gentamicin accumulation in E. faecalis: increased proton motive force-powered uptake and increased membrane permeability. We also found that a mammalian CA inhibitor could sensitize a variety of E. faecalis strains to killing with gentamicin. Given that mammalian CA inhibitors are frequently used to treat conditio